President Donald Trump has signed a government funding bill, ending a record 43-day shutdown that caused financial stress for ...
Sarepta Therapeutics, Inc. , the leader in precision genetic medicine for rare diseases, today announced an update to the prescribing information for ELEVIDYS (delandistrogene moxeparvovec-rokl), the ...
Company ranked #1 for Onboarding & Continuous Learning and Direct B2B Selling Use Cases in Gartner® Critical Capabilities for ...
Research and Development expenses for the third quarter of 2025 were $13.9 million compared to $11.5 million in the third quarter of 2024. The increase was primarily driven by higher headcount, higher ...